HL-A antigens and antibody response after influenza A vaccination. Decreased response associated with HL-A type W16.
We investigated possible associations of HL-A types and antibody-response patterns during clinical trials with a live, attenuated intranasal influenza A vaccine. After vaccination, subjects with HL-A type W16 had, as a group, a mean convalescent-phase hemagglutination-inhibiting antibody titer of 14, which was significantly lower (P less than 0.001) than the mean titer of 36 in subjects without Type W16. Of 25 subjects with a poor antibody response, 32 per cent had HL-A type W16, whereas only 5 per cent with a good response had Type W16. The mean titers in nasal secretions of five W16 subjects at 13 and 30 days were less than 3; in contrast, similar titers of 22 subjects without W16 were 8 and 9 respectively. The results suggest that the lower antibody response in W16 subjects is due to increased cellular resistance to infection rather than to a suppressed immune response because other subjects with W16 had normal antibody responses after vaccination with killed influenza vaccine.
D000914:Antibodies, Viral / Q000032:analysis*; D000917:Antibody Formation; D002986:Clinical Trials as Topic; D003289:Convalescence; D006680:HLA Antigens / Q000032:analysis*; D006385:Hemagglutination Inhibition Tests; D006649:Histocompatibility Antigens / Q000032:analysis*; D006801:Humans; D007111:Immunity, Cellular; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000494:pharmacology*; D007251:Influenza, Human / Q000276:immunology; D009666:Nose; D009975:Orthomyxoviridae / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000494:pharmacology
D000914:Antibodies, Viral; D006680:HLA Antigens; D006649:Histocompatibility Antigens; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated